Annual Report

Overview

The report describes Ypsomed's completed transformation into a pure-play injection specialist following the sale of Diabetes Care and Ypsotec. It reports group net sales of CHF 731.0 million and EBIT of CHF 246.1 million for 2025/26. The company reports SBTi-approved emissions targets, including a net-zero target for 2040 across the value chain. Selected sustainability indicators, including GHG emissions, waste, employee and integrity metrics, received PwC limited assurance.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2025-2026
Period: 1 April 2025 – 31 March 2026
Publication date: 20 May 2026
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
SBTi status
CDP score

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services